The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care
暂无分享,去创建一个
[1] Robert A Larsen,et al. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization. , 2008, AIDS patient care and STDs.
[2] D. Kroetz,et al. Adherence-resistance relationships to combination HIV antiretroviral therapy , 2007, Current HIV/AIDS reports.
[3] R. Steinbrook. Thailand and the compulsory licensing of efavirenz. , 2007, The New England journal of medicine.
[4] D. Mcintyre,et al. The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa – a primary data analysis , 2006, Cost effectiveness and resource allocation : C/E.
[5] Milton C Weinstein,et al. The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.
[6] A. Davidson,et al. Durability of adherence to antiretroviral therapy on initial and subsequent regimens. , 2006, AIDS patient care and STDs.
[7] M. Eaddy,et al. Methods for Evaluating Patient Adherence to Antidepressant Therapy: A Real-World Comparison of Adherence and Economic Outcomes , 2006, Medical care.
[8] Jerome H. Carter,et al. Distribution of health care expenditures for HIV-infected patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] L. Bekker,et al. Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa , 2005, PLoS medicine.
[10] A. Davidson,et al. Selective Drug Taking During Combination Antiretroviral Therapy in an Unselected Clinic Population , 2005, Journal of acquired immune deficiency syndromes.
[11] T. Flanigan,et al. Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients , 2005, AIDS.
[12] A. Wu,et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence , 2005, AIDS care.
[13] J. Ka,et al. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting , 2004 .
[14] N. Kumarasamy,et al. Generic antiretroviral drugs—will they be the answer to HIV in the developing world? , 2004, The Lancet.
[15] M. Peeters,et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial , 2004, The Lancet.
[16] A. Vanderplas,et al. The Costs of Non-Adherence to Oral Antihyperglycemic Medication in Individuals with Diabetes Mellitus and Concomitant Diabetes Mellitus and Cardiovascular Disease in a Managed Care Environment , 2004 .
[17] M. Postma,et al. A multicentre study of patient survival, disability, quality of life and cost of care , 2004, PharmacoEconomics.
[18] A. Vanderplas,et al. Economic Impact of Patient Adherence with Antidepressant Therapy Within a Managed Care Organization , 2003 .
[19] Milton C Weinstein,et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. , 2003, The American journal of medicine.
[20] Julio S. G. Montaner,et al. Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L , 2003, Annals of Internal Medicine.
[21] Evan Wood,et al. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? , 2003, AIDS.
[22] P. Gabow,et al. Denver Health: A Model for the Integration of a Public Hospital and Community Health Centers , 2003, Annals of Internal Medicine.
[23] R. Hogg,et al. Virologic and Immunologic Response, Clinical Progression, and Highly Active Antiretroviral Therapy Adherence , 2002, Journal of acquired immune deficiency syndromes.
[24] Dawn M Gencarelli. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? , 2002, NHPF issue brief.
[25] B. Yip,et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up , 2002, AIDS.
[26] A. Zolopa,et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.
[27] M. Weinstein,et al. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy , 2001, Antiviral therapy.
[28] D. Skiest,et al. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. , 2001 .
[29] M C Weinstein,et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.
[30] D. McCaffrey,et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.
[31] M. Youle,et al. Assessing the cost‐effectiveness of HAART for adults with HIV in England , 2001, HIV medicine.
[32] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[33] A. Gafni,et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. , 1999, AIDS.
[34] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[35] A. Davidson,et al. Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system. , 1993, Archives of internal medicine.
[36] D. B. Duncan. MULTIPLE RANGE AND MULTIPLE F TESTS , 1955 .
[37] J. Puig-Junoy,et al. Análisis coste-efectividad de la adhesión inicial a la terapia antirretroviral entre individuos infectados por el VIH en Belo Horizonte, Brasil , 2006 .
[38] Thomas Fleming,et al. Red book : pharmacy's fundamental reference , 2004 .